采用纳米工程化脂质载体在兔模型中实现依普利酮的有效眼部递药。

Effective Ocular Delivery of Eplerenone Using Nanoengineered Lipid Carriers in Rabbit Model.

机构信息

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

出版信息

Int J Nanomedicine. 2021 Jul 22;16:4985-5002. doi: 10.2147/IJN.S319814. eCollection 2021.

Abstract

BACKGROUND

Eplerenone (Epl) is a selective mineralocorticoid-receptor antagonist used for chronic central serous chorioretinopathy treatment. Our goal was to enhance the corneal performance of Epl-loaded nanostructured lipid carriers (NLCs) through surface modification using different coating polymers.

METHODS

Epl-loaded modified NLCs (Epl-loaded MNLCs) were prepared by coating the surface of Epl-loaded NLCs using different polymers, namely hyaluronic acid, chitosan oligosaccharide lactate, and hydrogenated collagen. A 3×4 full factorial design was used to evaluate the effect of the surface modification on the properties of the prepared systems. Selected optimal Epl-loaded MNLCs were further evaluated for in vitro drug release, morphology, pH, rheological properties, corneal mucoadhesion, irritation, and penetration.

RESULTS

Epl-loaded MNLCs were successfully prepared with high drug-entrapment efficiency and nanosized particles with low size distribution. Transmission electron microscopy revealed nanosized spherical particles surrounded by a coating layer of the surface modifier. The pH, refractive index, and viscosity results of the Epl-loaded MNLCs confirmed the ocular compatibility of the systems with no blurring of vision. The safety and ocular tolerance of the optimal MNLCs were confirmed using the hen's egg test on chorioallantoic membrane and by histopathological evaluation of rabbit eyes treated with the optimal systems. Confocal laser-scanning microscopy of corneal surfaces confirmed successful transcorneal permeation of the Epl-loaded MNLCs compared to the unmodified Epl-loaded NLCs, revealed by higher corneal fluorescence intensity at all time intervals.

CONCLUSION

Overall, the results confirmed the potential of Epl-loaded MNLCs as a direct approach for Epl ocular delivery.

摘要

背景

依普利酮(Epl)是一种选择性的盐皮质激素受体拮抗剂,用于治疗慢性中心性浆液性脉络膜视网膜病变。我们的目标是通过使用不同的涂层聚合物对载有依普利酮的纳米结构化脂质载体(NLC)进行表面修饰,从而提高其角膜性能。

方法

通过使用不同的聚合物(即透明质酸、壳聚糖低聚糖乳酸盐和氢化胶原)对载有依普利酮的 NLC(Epl-loaded NLC)的表面进行涂层,制备载有 Epl 的修饰 NLC(Epl-loaded MNLC)。采用 3×4 完全析因设计来评估表面修饰对所制备系统性质的影响。选择最佳的载有 Epl 的 MNLC 进一步进行体外药物释放、形态、pH 值、流变学性质、角膜粘膜粘附性、刺激性和穿透性评价。

结果

成功制备了载有 Epl 的 MNLC,具有高载药效率和纳米级的小粒径分布。透射电子显微镜显示,纳米级的球形颗粒被表面修饰剂的涂层所包围。Epl-loaded MNLC 的 pH 值、折射率和粘度结果证实了这些系统的眼用相容性,不会导致视力模糊。通过鸡胚绒毛尿囊膜试验和对用最佳系统处理的兔眼进行组织病理学评估,证实了最佳 MNLC 的安全性和眼部耐受性。角膜表面的共聚焦激光扫描显微镜证实,与未修饰的载有 Epl 的 NLC 相比,载有 Epl 的 MNLC 能够成功穿透角膜,所有时间间隔的角膜荧光强度都更高。

结论

总的来说,这些结果证实了载有 Epl 的 MNLC 作为依普利酮眼部给药的直接方法的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8855/8318821/d40a710d9e55/IJN-16-4985-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索